Segment Disclosure (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Summary of Net Loss Related To Segment Expenses

The following table presents information about reported segment revenues, significant segment expenses, and segment loss:

	Year Ended December 31,
	2025			2024			2023
Collaboration revenue	$	7,500		$	—		$	—
Less:
Direct external research and development costs
Azetukalner		165,950			106,806			89,303
Pain programs (XEN1701, XEN1120)		7,510			4,795			—
Pre-clinical, discovery and other programs		24,387			16,751			20,704
Personnel-related expenses		89,703			68,340			47,739
Stock-based compensation		53,707			50,717			32,372
Other research and development costs		12,519			11,232			9,560
Other general and administrative costs		26,794			20,657			14,376
Interest income		(26,828	)		(41,943	)		(27,620	)
Other segment items(1)		(332	)		(3,025	)		(4,041	)
Net loss		(345,910	)		(234,330	)		(182,393	)

(1)Other segment items include foreign exchange gain (loss), unrealized fair value gain on trading securities, and income tax recovery (expense).